Journal of Clinical Oncology

Vol. 43, Issue 16_suppl Issue 16_suppl 2025
6439
Articles

Articles in this Issue

A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION).

Rupesh Kotecha, Yazmin Odia, Zhijian Chen et al. Jun 01, 2025 pp. 2022-2022 10.1200/jco.2025.43.16_suppl.2022

2022 Background: Azeliragon is an oral, brain penetrating small molecule inhibitor of the receptor for advanced glycation end-products (RAGE), reducing ne...

Oligometastatic gastrointestinal stromal tumor: Association between treatment type, metastatic pattern, and survival.

Tanner Hill, Hayes Pearce, Mohammad Saleh et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23522

e23522 Background: Treatment of oligometastatic gastrointestinal stromal tumor (GIST), defined as the presence of no more...

Fecal microbiota transplantation combined with sintilimab and SOX as first-line treatment for advanced gastric cancer (FMT-JSNO-01): A prospective, multicenter, double-blind, randomized placebo-controlled phase II trial.

Wenyu Zhu, Ya Xue, Qiong Wang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps2702

TPS2702 Background: Chemotherapy in combination with immunotherapy has emerged as the first-line(1L) standard of care for gastric cancer (GC) patients(pts...

The uTRACT registry: A single-arm, multicenter, prospective, and retrospective registry study to evaluate the real-world use of UGN-101 in participants with upper tract urothelial carcinoma (UTUC) in the United States.

Adam Feldman, Yair Lotan, Soloman Woldu et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps4629

TPS4629 Background: Upper tract urothelial carcinoma (UTUC) constitutes 5–10% of primary urothelial carcinomas, affecting two in 100,000 people in the US...

PRESCIENTai, an AI-based digital histopathological image signature for risk of late distant recurrence and extended endocrine therapy (EET) benefit in hormone receptor–positive breast cancer.

Eleftherios P. Mamounas, Ming Chen, Tanner Freeman et al. Jun 01, 2025 pp. 1556-1556 10.1200/jco.2025.43.16_suppl.1556

1556 Background: A subset of patients (pts) with hormone receptor-positive (HR+) breast cancer (BC) experiences late distant recurrence (DR) and is more l...

Contemporary trends and survival outcomes in young-onset vs. average-onset metastatic colorectal cancer: A real-world comparison.

Chadane Thompson, Shalva Eliava, Areeba Nayyer et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15614

e15614 Background: Colorectal cancer (CRC) is the third most common cancer worldwide. It is a major cause of morbidity and mortality, typically affecting...

A novel nomogram for predicting treatment and prognosis in primary gastric squamous cell carcinoma (PGSCC).

Salsabeel Aljawabrah, Sakhr Alshwayyat, Kholoud Alqasem et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16092

e16092 Background: PGSCC is an aggressive tumor that accounts for 0.5% of all gastric cancer cases. Its poor prognosis and lack of management guidelines m...

Unmet educational needs, challenges, and potential benefits in expanding prescriber bases in oncology and prostate cancer: A scoping review.

Axel Stuart Merseburger, Amit Bahl, Suneel Dinkar Mundle et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13511

e13511 Background: Expanding prescriber bases is essential for more equitable and holistic healthcare, particularly amid the global healthcare workforce c...

SECuRE: A dose escalation/expansion study to assess the anti-tumor efficacy of <sup>67</sup> Cu-SAR-bisPSMA in patients with metastatic castrate resistant prostate cancer.

Geoffrey Bates Johnson, Eva Lengyelova, Luke Nordquist et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps5125

TPS5125 Background: Prostate cancer (PC) is common and despite recent advances in treatment options, patients with metastatic disease still have poor outc...

The use of an electronic medical record (EMR) best practice advisory (BPA) to facilitate oncofertility referrals and fertility preservation.

Alexandra Marie Meeter, Disha Sawhney, Eileen S. Seltzer et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23239

e23239 Background: The incidence of young adult (YA) and early onset cancer has increased significantly over the past two decades, necessitating an increa...

Effects of hyperglycemia on in-hospital outcomes on gastric and esophageal cancer patients suffering from cachexia: Insights from the National Inpatient Sample.

Suriya Baskar, Nidhi Prasad, Surbhi Singh Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16089

e16089 Background: Cachexia is a debilitating syndrome commonly associated with gastric and esophageal cancer (GEC). Cancer patients may experience hyperg...

Empowering patient voices in oncology: The role of patient advocacy in medical education and research collaboration.

Donna Gabriel, Rebecca Weaver, Jill Libles Feldman Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e21023

e21023 Background: Integrating patient advocacy into medical education and research fosters a collaborative approach to addressing gaps in oncology care a...

Effectiveness of a multidomain mHealth-based intervention in enhancing recovery and quality of life for esophageal cancer patients undergoing esophagectomy.

Xiaodong Su, Xu Zhang, Yan Guo et al. Jun 01, 2025 pp. 4071-4071 10.1200/jco.2025.43.16_suppl.4071

4071 Background: Esophagectomy, a primary treatment for esophageal cancer (EC), often compromises patients' quality of life (QOL), leading to malnutrition...

Correlation of carcinoembryonic antigen with survival in patients with colorectal liver metastases receiving yttrium-90 radioembolization treatment.

Chinonso Ani, Patrick Doyle, Meaghan Dendy Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e15509

e15509 Background: Colorectal liver metastases are a leading cause of cancer-related mortality in patients with colorectal cancer. Yttrium-90 (Y-90) radio...

Reducing risks of surgeries and complications in von Hippel-Lindau disease with belzutifan treatment in China.

Yue Pan, Xiaodong Guan, Ying Xiao et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e23063

e23063 Background: Von Hippel-Lindau (VHL) disease is a rare hereditary disorder causing neoplasms in multiple organs. Prevalence estimates range from 1:3...

Oregovomab in combination with non-platinum chemotherapy for the treatment of PARP inhibitor– and platinum-resistant ovarian cancer: A two-cohort, single-arm phase 2 study (OPERA/KGOG3065/APGOT-OV6).

Junsik Park, Hyun Woong Cho, Myong Cheol Lim et al. Jun 01, 2025 pp. 5587-5587 10.1200/jco.2025.43.16_suppl.5587

5587 Background: Oregovomab, an investigational murine monoclonal antibody against CA-125, has shown promising efficacy in a phase 2 study in patients wit...

Clinical characteristics and cancer spectrum among breast cancer patients with TP53 germline mutation from a single institution.

Ashley Woodson, Aydah Al-Awadhi, Angelica M. Gutierrez et al. Jun 01, 2025 pp. 10609-10609 10.1200/jco.2025.43.16_suppl.10609

10609 Background: Li-Fraumeni syndrome (LFS), due to germline TP53 mutations, is associated with elevated risks of multiple cancers including early onset...

Molecular heterogeneity in dMMR/MSI-H endometrial cancer in the US.

Rutugandha Paranjpe, Cai Chen, Yezhou Sun et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e17643

e17643 Background: Deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) are actionable biomarkers in endometrial cancer (EC). KEYNOTE-...

Preliminary efficacy and safety results of tislelizumab (T) and axitinib (A) combined with stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic renal cell carcinoma (omRCC): A single-center phase II study.

Wei Zhang, Qingyang Pang, Qingshui Wang et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16503

e16503 Background: SBRT, a novel treatment modality by directly targeting tumor sites using high dose of radiation, has become standard of care for pts wi...

A phase II study of ACR-368 and low dose gemcitabine combination therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Robin Park, Dan Paul Zandberg, Jean-Marie Cuillerot et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.tps6110

TPS6110 Background: Safe and efficacious therapeutic options for patients with recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSC...

Distinguishing tumor vs. clonal hematopoiesis (CH)–derived <i>TP53</i> and <i>BRCA1/2</i> alterations in ovarian cancer liquid biopsies with a predictive algorithm to inform clinical decision-making.

Natalie Danziger, Julia A. Elvin, Ryon P. Graf et al. Jun 01, 2025 pp. 5592-5592 10.1200/jco.2025.43.16_suppl.5592

5592 Background: CH results from mutations in hematopoietic stem cells and can occur in clinically relevant genes that are detected in liquid biopsy (LBx)...

Real-world insights into cardiometabolic comorbidities and their role in triple-negative breast cancer outcomes.

Jasmin Hundal, Asfand Yar Cheema, Akram Abushamma et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e13157

e13157 Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with limited treatment options and poor prognosis. While the advent of ch...

Exploring burden of liver malignancies due to NASH: An analysis of GBD-2021.

Muhammad Asjad Saleem, Shree Rath, Ayesha Saleem et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16298

e16298 Background: The growing burden of obesity, type 2 diabetes, and metabolic risk factors has driven a rise in non-alcoholic steatohepatitis (NASH)-re...

Clinical outcomes of chemotherapy with or without intravesical BCG in NMIBC patients: A Bayesian network meta-analysis.

Arwa M. Ibrahim, Shree Rath, M. Rafiqul Islam et al. Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16599

e16599 Background: Non-muscle-invasive bladder cancer (NMIBC) is a recurrent urinary bladder malignancy traditionally treated with intravesical Bacillus C...

Real world evidence for patients with advanced and metastatic pancreatic cancer treated with sacituzumab govitecan: A retrospective trial in China.

Xiaofei Zhang Jun 01, 2025 10.1200/jco.2025.43.16_suppl.e16412

e16412 Background: Pancreatic cancer is a malignancy with poor prognosis and lack of effective therapeutic targets. Chemotherapy remains the foundation of...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page